Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There is increasing interest in the use of combination therapy for rheumatoid arthritis and in the possibility of combining the conventional drug approach with newer biological therapies. Animal models of arthritis provide important tools for evaluating novel forms of therapy and for eludicating mechanisms of drug action. In this paper, we review the results of our own research into combination therapy in collagen-induced arthritis using biological therapies such as anti-tumor necrosis factor alpha, anti-CD4, and anti-interleukin 12 monoclonal antibodies, and small molecular weight compounds such as cyclosporin and the phosphodiesterase IV (PDE IV) inhibitor rolipram.

Type

Journal article

Journal

Clinical and experimental rheumatology

Publication Date

11/1999

Volume

17

Pages

S115 - S120

Addresses

Kennedy Institute of Rheumatology, London, UK.

Keywords

Animals, Mice, Arthritis, Rheumatoid, Disease Models, Animal, Collagen, Antirheumatic Agents, Immunotherapy, Drug Therapy, Combination